title: Androgen deprivation increases p300 expression in prostate cancer cells.
abstract: Standard therapy for nonorgan confined prostate cancer aims to block the production or action of androgens. Although initially successful, antiandrogen therapy eventually fails and androgen depletion independent (ADI) disease emerges. Remarkably, ADI prostate cancers still rely on a functional androgen receptor (AR). Aberrant expression of coregulatory proteins required for the formation of productive AR transcriptional complexes is critical for ADI AR activation. Previously, we have shown that the transcriptional coactivator p300 is required for ADI activation of the AR and is up-regulated in prostate cancer, in which its expression is associated with cell proliferation and predicts aggressive tumor features. The mechanism responsible for the deregulated expression of p300, however, remains elusive. Here, we show that p300 expression in prostate cancer cells is subject to androgen regulation. In several prostate cancer model systems, addition of synthetic and natural androgens led to decreased expression of p300 in a time-dependent and dose-dependent manner. Experiments using AR antagonists or small interfering RNA targeting the AR revealed that down-regulation of p300 depends entirely on the presence of a functional AR. It is noteworthy that androgens down-regulated p300 protein expression while leaving messenger levels unaltered. Conversely, both short-term and long-term androgen deprivation resulted in marked up-regulation of p300 expression. The androgen deprivation-induced increase in p300 expression was not affected by the addition of cytokines or growth factors or by cotreatment with antiandrogens. Moreover, increased p300 expression upon androgen starvation is crucial for prostate cancer cell proliferation, as loss of p300 expression severely reduces expression of cyclins governing G(1)-S and G(2)-M cell cycle transition and decreases 5-bromo-2'-deoxyuridine incorporation.
authors.affiliation: Departments of Urology/Biochemistry and Molecular Biology and Laboratory Medicine/Pathology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Hannelore V
authors.initials: HV
authors.lastname: Heemers
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Sebo
authors.forename: Jose D
authors.initials: JD
authors.lastname: Debes
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Regan
authors.forename: Kristin A
authors.initials: KA
authors.lastname: Raclaw
authors.forename: Linda M
authors.initials: LM
authors.lastname: Murphy
authors.forename: Alfred
authors.initials: A
authors.lastname: Hobisch
authors.forename: Zoran
authors.initials: Z
authors.lastname: Culig
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Tindall
mesh_terms: D000728:Androgens / Q000172:deficiency*; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D015536:Down-Regulation; D050881:E1A-Associated p300 Protein / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011944:Receptors, Androgen / Q000096:biosynthesis; D015854:Up-Regulation
chemical_list: D000728:Androgens; D012333:RNA, Messenger; D011944:Receptors, Androgen; D050881:E1A-Associated p300 Protein; C494360:EP300 protein, human